相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Javier Cortes et al.
LANCET (2011)
A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies
Sanjay Goel et al.
CLINICAL CANCER RESEARCH (2009)
Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors
Antoinette R. Tan et al.
CLINICAL CANCER RESEARCH (2009)
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: A National Cancer Institute Organ Dysfunction Working Group Study
Timothy W. Synold et al.
CLINICAL CANCER RESEARCH (2007)
Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin
Donnette A. Dabydeen et al.
MOLECULAR PHARMACOLOGY (2006)
Peripheral neuropathy induced by microtubule-stabilizing agents
JJ Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth
MA Jordan et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389
G Kuznetsov et al.
CANCER RESEARCH (2004)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
